{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:54:06Z","timestamp":1790862846444,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fund for Scientific Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtha.2025.06.016","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T15:47:02Z","timestamp":1750261622000},"page":"3173-3184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effect of heparins, direct oral anticoagulants, and factor XII\/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6701-9417","authenticated-orcid":false,"given":"Michael","family":"Hardy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Thonon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Douxfils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Vassart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Gouin\u2013Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lessire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lecompte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mullier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.06.016_bib1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/ACO.0000000000000524","article-title":"NonOperating Room Anesthesia: distancing from invasive surgery, embracing the era of interventional medicine","volume":"30","author":"Dabu\u2013Bondoc","year":"2017","journal-title":"Curr Opin Anaesthesiol"},{"key":"10.1016\/j.jtha.2025.06.016_bib2","first-page":"1","article-title":"Interventional medicine","volume":"1","author":"Cheng","year":"2018","journal-title":"J Interv Med"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2025.06.016_bib3","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1111\/jth.12961","article-title":"Medical device-induced thrombosis: what causes it and how can we prevent it?","volume":"13","author":"Jaffer","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.016_bib4","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.016_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300067","article-title":"Apixaban or warfarin in patients with an On-X mechanical aortic valve","volume":"2","author":"Wang","year":"2023","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.jtha.2025.06.016_bib6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1213\/ANE.0000000000006019","article-title":"Rivaroxaban reduces the dabigatran dose required for anticoagulation during simulated cardiopulmonary bypass","volume":"135","author":"Nadtochiy","year":"2022","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jtha.2025.06.016_bib7","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1213\/ANE.0000000000005089","article-title":"High-dose dabigatran is an effective anticoagulant for simulated cardiopulmonary bypass using human blood","volume":"132","author":"Nadtochiy","year":"2021","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jtha.2025.06.016_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1160\/TH13-12-1047","article-title":"Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits","volume":"112","author":"Yau","year":"2014","journal-title":"Thromb Haemost"},{"issue":"Suppl 2","key":"10.1016\/j.jtha.2025.06.016_bib9","article-title":"Heparin is more effective than apixaban in inhibiting in vitro contact activated coagulation","volume":"41","author":"Engelen","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.06.016_bib10","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1538-7836.2007.02477.x","article-title":"Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation","volume":"5","author":"Gerotziafas","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.016_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0049-3848(91)90400-Q","article-title":"Involvement of the extrinsic pathway in the activities of low-molecular-weight heparins","volume":"14","author":"Norrheim","year":"1991","journal-title":"Thromb Res Suppl"},{"key":"10.1016\/j.jtha.2025.06.016_bib12","first-page":"258","article-title":"Determination of the levels of unfractionated and low-molecular-weight heparins in plasma: their effect on thrombin-mediated feedback reactions in vivo. Preliminary results after subcutaneous injection","volume":"21","author":"Hemker","year":"1991","journal-title":"Haemostasis"},{"key":"10.1016\/j.jtha.2025.06.016_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2024.109194","article-title":"Development and validation of an in vitro model to study thrombin generation on the surface of catheters in platelet-poor and platelet-rich plasma","volume":"244","author":"Hardy","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.06.016_bib14","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.016_bib15","doi-asserted-by":"crossref","first-page":"12203","DOI":"10.1021\/acs.jmedchem.3c00795","article-title":"Design and preclinical characterization program toward Asundexian (BAY 2433334), an oral factor XIa inhibitor for the prevention and treatment of thromboembolic disorders","volume":"66","author":"Roehrig","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.jtha.2025.06.016_bib16","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","article-title":"Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy","volume":"65","author":"Dilger","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.jtha.2025.06.016_bib17","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.016_bib18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus rivaroxaban in patients with atrial fibrillation","volume":"392","author":"Ruff","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.016_bib19","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.016_bib20","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.06.016_bib21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.016_bib22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"Buller","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.016_bib23","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.016_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.06.016_bib25","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.016_bib26","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41591-023-02794-7","article-title":"Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial","volume":"30","author":"Weitz","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2025.06.016_bib27","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.016_bib28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","article-title":"Phase 2 study of the factor XI antisense inhibitor IONIS-FXI(Rx) in patients with ESRD","volume":"7","author":"Walsh","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"2 Suppl","key":"10.1016\/j.jtha.2025.06.016_bib29","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.06.016_bib30","series-title":"Lovenox 100 mg\/1 mL solution for injection [SmPC]","year":"2017"},{"key":"10.1016\/j.jtha.2025.06.016_bib31","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1055\/s-0038-1649967","article-title":"Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107\/Org31540) with high affinity to antithrombin III in man","volume":"74","author":"Boneu","year":"1995","journal-title":"Thromb Haemost"},{"issue":"Suppl 2","key":"10.1016\/j.jtha.2025.06.016_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-200241002-00001","article-title":"The pharmacokinetics of fondaparinux sodium in healthy volunteers","volume":"41","author":"Donat","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2025.06.016_bib33","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.016_bib34","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jth.15439","article-title":"First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa","volume":"19","author":"Thomas","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.016_bib35","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jtha.2025.06.016_bib36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.016_bib37","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/ijlh.13356","article-title":"Are the DOAC plasma level thresholds appropriate for clinical decision-making? A reappraisal using thrombin generation testing","volume":"43","author":"Evrard","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.06.016_bib38","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1160\/TH08-10-0670","article-title":"Monitoring thrombin generation: is addition of corn trypsin inhibitor needed?","volume":"101","author":"Spronk","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.016_bib39","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.3390\/jcm10184240","article-title":"Running after activated clotting time values in patients receiving direct oral anticoagulants: a potentially dangerous race. results from a prospective study in atrial fibrillation catheter ablation procedures","volume":"10","author":"Benali","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2025.06.016_bib40","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/j.1552-4604.1988.tb03184.x","article-title":"The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg","volume":"28","author":"Frydman","year":"1988","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.06.016_bib41","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1055\/s-0038-1646990","article-title":"The mode of action of heparin in plasma","volume":"60","author":"Beguin","year":"1988","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.016_bib42","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1749-6632.1989.tb22493.x","article-title":"Effect of heparin on the inhibition of the contact system enzymes","volume":"556","author":"Colman","year":"1989","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jtha.2025.06.016_bib43","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.1182\/blood-2011-07-364141","article-title":"Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo","volume":"118","author":"Yau","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.016_bib44","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.016_bib45","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1161\/CIRCULATIONAHA.108.789479","volume":"118","author":"Mehta","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.016_bib46","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002322","article-title":"Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation","volume":"4","author":"Jaffer","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2025.06.016_bib47","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.athoracsur.2019.10.091","article-title":"Rivaroxaban and dabigatran for suppression of mechanical heart valve-induced thrombin generation","volume":"110","author":"Jaffer","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtha.2025.06.016_bib48","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/j.thromres.2010.06.011","article-title":"In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves","volume":"126","author":"Maegdefessel","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.06.016_bib49","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.thromres.2024.03.001","article-title":"Asundexian in atrial fibrillation: can pharmacodynamic data explain the failure?","volume":"236","author":"Vassart","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.06.016_bib50","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.016_bib51","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J Mol Biol"},{"key":"10.1016\/j.jtha.2025.06.016_bib52","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0049-3848(94)90253-4","article-title":"Calcium threshold in human plasma clotting kinetics","volume":"75","author":"Ataullakhanov","year":"1994","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.06.016_bib53","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1021\/bi00387a005","article-title":"Role of calcium ions and the heavy chain of factor XIa in the activation of human coagulation factor IX","volume":"26","author":"Sinha","year":"1987","journal-title":"Biochemistry"},{"key":"10.1016\/j.jtha.2025.06.016_bib54","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1111\/jth.12707","article-title":"The effect of corn trypsin inhibitor and inhibiting antibodies for FXIa and FXIIa on coagulation of plasma and whole blood","volume":"12","author":"Hansson","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.016_bib55","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/jth.12812","article-title":"The effect of corn trypsin inhibitor and inhibiting antibodies for FXIa and FXIIa on coagulation of plasma and whole blood: comment","volume":"13","author":"Butenas","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.016_bib56","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1111\/j.1538-7836.2004.00964.x","article-title":"Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition","volume":"2","author":"Luddington","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2025.06.016_bib57","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood-2019-130875","article-title":"Novel thermostable inhibitor of contact activation TICA effectively blocks contact activation in low tissue factor thrombin generation","volume":"134","author":"Van De Berg","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.016_bib58","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2014810118","article-title":"Kallikrein directly interacts with and activates factor IX, resulting in thrombin generation and fibrin formation independent of factor XI","volume":"118","author":"Kearney","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2025.06.016_bib59","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2019.08.1028","article-title":"Anticoagulation with an inhibitor of factors XIa and XIIa during cardiopulmonary bypass","volume":"74","author":"Pireaux","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.06.016_bib60","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1373\/clinchem.2015.248625","article-title":"Thrombin generation assay and its application in the clinical laboratory","volume":"62","author":"Tripodi","year":"2016","journal-title":"Clin Chem"},{"key":"10.1016\/j.jtha.2025.06.016_bib61","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1182\/blood-2011-07-368811","article-title":"Polyphosphate is a cofactor for the activation of factor XI by thrombin","volume":"118","author":"Choi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.016_bib62","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bcmd.2017.04.006","article-title":"Platelet factor XI: intracellular localization and mRNA splicing following platelet activation","volume":"69","author":"Zucker","year":"2018","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.jtha.2025.06.016_bib63","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2014-12-616565","article-title":"Sample conditions determine the ability of thrombin generation parameters to identify bleeding phenotype in FXI deficiency","volume":"126","author":"Pike","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.016_bib64","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2516.2010.02246.x","article-title":"Thrombin generation in patients with factor XI deficiency and clinical bleeding risk","volume":"16","author":"Rugeri","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.06.016_bib65","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1477-9560-3-16","article-title":"Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay","volume":"3","author":"Gerotziafas","year":"2005","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2025.06.016_bib66","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1076029607303763","article-title":"Intrinsic hemostasis activation by freezing and thawing of plasma","volume":"15","author":"Stief","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.06.016_bib67","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.thromres.2018.10.005","article-title":"The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generation","volume":"171","author":"Bloemen","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.06.016_bib68","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/j.1538-7836.2010.03822.x","article-title":"The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by alpha-macroglobulin-thrombin","volume":"8","author":"Wagenvoord","year":"2010","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625004027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625004027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:25:39Z","timestamp":1790817939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625004027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":68,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1538783625004027"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.016","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of heparins, direct oral anticoagulants, and factor XII\/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}